- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03925649
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI
September 24, 2025 updated by: Hope Biosciences LLC
Individual Patient Expanded Access IND (Investigational New Drug) of Autologous HB-adMSCs for the Treatment of Spinal Cord Injury
This study is expanded access to an Investigational New Drug (IND) for an individual patient with spinal cord injury (SCI) at cervical spine 5-6 (C 5-6) designed to provide access to autologous adipose-derived mesenchymal stem cells (HB-adMSCs)
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Detailed Description
This is an expanded access single-dose study with the primary goal of treatment submitted at the request of an individual patient with complete C5-6 spinal cord injury (SCI) resulting in quadriplegia who does not qualify for any current clinical trials and for whom there are no other FDA approved fully restorative treatments.
The overall objective of this study is to evaluate patient's response, adverse events and serious adverse events (AE/SAEs), and cell expansion characteristics of a single intravenous (IV) infusion of autologous adipose-derived mesenchymal stem cells (HB-adMSCs) in a subject with complete SCI resulting in quadriplegia.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
- Intermediate-size Population
- Treatment IND/Protocol
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
- Cognitively intact, capable of giving informed consent
- Clinical diagnosis of a non-penetrating traumatic SCI
- Asia Impairment Scale grade of A, B, or C
Exclusion Criteria:
Prior history of:
- Brain injury
- Recent or ongoing infection
- Clinically significant cardiovascular, lung, renal, hepatic or endocrine disease,
- Neurodegenerative disorders
- Cancer
- Immunosuppression as defined by WBC<3,000 cells/ml at baseline screening,
- HIV+
- Chemical or ETOH dependency
- Having a contraindication to MRI scans
- Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSC administration
- Participation in other interventional research studies
- Unwillingness to return for follow-up visits
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
April 16, 2019
First Submitted That Met QC Criteria
April 18, 2019
First Posted (Actual)
April 24, 2019
Study Record Updates
Last Update Posted (Estimated)
September 29, 2025
Last Update Submitted That Met QC Criteria
September 24, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HBSCI01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.